MCA
GILD icon

Maryland Capital Advisors’s Gilead Sciences GILD Stock Holding History

Maryland Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$746 Hold
5
– – ﹤0.01% 260
2026
Q2 		$632 Buy
+5
New +$659 ﹤0.01% 272

Other funds holding GILD

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Confluence Investment Management
Confluence Investment Management St. Louis, Missouri $5.97B AUM 5.11% 1-Year Est. Return
Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
IFM Investors
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
CA
CapWealth Advisors Franklin, Tennessee $1.32B AUM 21.6% 1-Year Est. Return

Maryland Capital Advisors's GILD Position: Q3 2026 in Review

Maryland Capital Advisors held its Gilead Sciences (GILD) position steady in Q3 2026 at 5 shares worth $746. The position accounts for ﹤0.01% of the portfolio, ranked #260.

Maryland Capital Advisors first reported a position in GILD in Q2 2026 and has held it in 2 quarters since. 336 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

  • Maryland Capital Advisors held 5 shares of Gilead Sciences worth $746 as of Q3 2026.
  • Maryland Capital Advisors left its Gilead Sciences share count unchanged in Q3 2026.
  • Gilead Sciences made up ﹤0.01% of Maryland Capital Advisors's portfolio in Q3 2026, its #260 holding.
  • Maryland Capital Advisors first reported a position in Gilead Sciences in Q2 2026 and has held it in 2 quarters since.
  • 336 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on Maryland Capital Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.